More
The International Agency for Research on Cancer (IARC) is working with partners to assess the impact of coronavirus disease (COVID-19) on cancer and cancer prevention. Two recent papers, one a systematic review of literature on COVID-19 therapies and anticancer drugs and the other a study of the clinical characteristics of patients with metastatic prostate cancer who are infected with COVID-19, are examples of this international effort to investigate the effects of COVID-19 on cancer mortality and survival.
The literature review describes potential preferred treatments for COVID-19 and their interactions with the most commonly used antineoplastic agents. The study of the clinical characteristics of patients with metastatic prostate cancer who are infected with COVID-19 provides observations from a small sample of patients with prostate cancer in South Italy that seem to align with results from other regions of the world in relation to COVID-19 treatment, hormone levels, and options for the management of patients with prostate cancer who are positive for COVID-19.
These articles provide an important contribution for patients with cancer and the health-care professionals who are managing their care during the COVID-19 pandemic.
Di Lorenzo G, Di Trolio R, Kozlakidis Z, Busto G, Ingenito C, Buonerba L, et al.
COVID 19 therapies and anti-cancer drugs: a systematic review of recent literature
Crit Rev Oncol Hematol, Published online 21 May 2020;
https://doi.org/10.1016/j.critrevonc.2020.102991
Di Lorenzo G, Buonerba L, Ingenito C, Crocetto F, Buonerba C, Libroia A, et al.
Clinical characteristics of metastatic prostate cancer patients infected with COVID-19 in South Italy
Oncology, Published online 22 June 2020;
https://doi.org/10.1159/000509434
WHO Classification of Tumours: Head and Neck Tumours is now available in print format.
Head a...
The International Agency for Research on Cancer (IARC) is saddened by the passing of Professor JÃ...
The International Agency for Research on Cancer (IARC) is hosting the meeting of the Advisory Gro...